NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

NeoStem Story

NeoStem’s story begins with the simple idea that we can use modern science to harness and enhance the healing mechanisms that already exist inside our own bodies.

NeoStem is leading the paradigm shift in modern medicine towards cell therapy – a shift away from treating disease with drugs and toward treating disease with the body’s own cells. Since 2006, NeoStem has been led by physician and business executive Dr. Robin L. Smith. Dr. Smith and her team saw the potential to take part in this shift by developing the cell therapies that will potentially change the way that we treat illness and chronic disease.

Just as the cell therapy industry has grown and developed over the past decade, NeoStem too has transformed itself through a series of strategic mergers and acquisitions. First focusing on adult stem cells, and then expanding into therapeutics that work with other cell sources, NeoStem has seized upon the opportunity to be more than just a participant in the emerging cell therapy industry, instead choosing to be a driving force for growth and advancement in cell therapy research, development and manufacturing.

For more than 15 years, PCT (now a NeoStem subsidiary) has been providing market-leading contract development and manufacturing services to a wide range of clients in the regenerative medicine industry. With NeoStem’s acquisition of PCT in 2011, NeoStem gained access for its products to PCT’s world-class development expertise and manufacturing capabilities, as well as to a unique platform offering experience with multiple cell types. Also in 2011, NeoStem acquired the technologies for its Ischemic Repair Program and Immune Modulation Program, expanding the Company’s development pipeline. In 2014 NeoStem’s pipeline expanded further with its acquisition of California Stem Cell, creating the Company’s Targeted Cancer Immunotherapy Program and beginning NeoStem’s investigation into cancer therapeutics. Along the way, the Company has sustained its successful growth by investing in a management team of seasoned industry executives and adding clinical programs for new indications.

Today, NeoStem leverages its revenue-generating platform of expert capabilities for the manufacture of cell therapies across multiple internal and client development programs, and with each new clinical and regulatory milestone we and our peers in the industry achieve, our passion and excitement about the potential for cell therapy grows. The NeoStem story is the story of experienced management, dedicated employees, industry-leading expertise and a revolutionary spirit hard at work to make the potential of cell therapy a reality.

Key Milestones


2014

  • NeoStem acquires California Stem Cell, Inc., developing NeoStem’s Targeted Cancer Immunotherapy Program. Learn More »
  • Begins research collaboration for treatment of skin wounds in scleroderma Learn More »
  • Announced second research collaboration with Mass. Eye and Ear/Schepens Eye Research Institute exploring NeoStem’s VSEL™ Technology for retinal repair Learn More »
  • Expanded Treg international patent portfolio with granting of patent in Japan Learn More »
  • Expanded CD34 cell patent portfolio with new US and European patent allowances Learn More »

2013

  • Completed patient enrollment in Phase 2 AMR-001 trial for prevention of adverse cardiovascular events following a heart attack. Learn More »
  • NeoStem ranked #1 fastest growing company in Tri-State region on Deloitte’s 2012 Technology Fast 500™ for second year in a row. Learn More »
  • NeoStem begins trading on NASDAQ stock market. Learn More »
  • Advances autoimmune platform through UCSF collaboration. Learn More »
  • Held Second International Vatican Adult Stem Cell Conference, in partnership with the Vatican’s Pontifical Council for Culture in April. Learn More »
  • Further expansions of NeoStem’s cardiovascular disease intellectual property coverage. Learn More »

2012

  • Began patient enrollment for Phase 2 AMR-001 trial for prevention of adverse cardiovascular events following a heart attack. Learn More »
  • Expanded NeoStem’s cardiovascular disease intellectual property protection coverage beyond target indication for AMR-001. Learn More »
  • Awarded $595,252 grant from NIAID for the development of VSELTM Technology for radiation exposure. Learn More »
  • Awarded $1.2 million grant from NIH for the first clinical study of VSELTM Technology in humans for periodontitis. Learn More »
  • NeoStem ranked #1 fastest growing company in Tri-State region on Deloitte’s 2012 Technology Fast 500™. Learn More »

2011

  • Held First International Vatican Adult Stem Cell Conference, in partnership with the Vatican’s Pontifical Council for Culture in November. Learn More »
  • Acquired Amorcyte with a Phase 2 ready asset for acute myocardial infarction and a Phase 1 ready asset for congestive heart failure. Learn More »
  • Acquired Progenitor Cell Therapy, whose services include cell therapy, contract manufacturing, and cord blood banking
  • Acquired an 80% ownership of Athelos, a company developing a T-cell therapeutic with potential for a range of auto-immune conditions. Learn More »
  • Awarded and received over $1.7 million from Department of Defense Peer Reviewed Medical Research Program to employ VSEL™ technology to treat osteoporosis and improve bone health. Learn More »

2010

  • Awarded contract with U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center to evaluate the use of adult stem cells for rapid wound healing. Learn More »
  • NeoStem named “Best Stem Cell Company” in The New Economy’s 2010 Biotech Awards. Learn More »
  • Announced breakthrough partnership between the Vatican’s Pontifical Council for Culture and the Stem For Life Foundation. Learn More »
  • PCT announced the first stage of its Allendale facility build complete *

* Prior to NeoStem acquisition

For Key Milestones in the history of Progenitor Cell Therapy, please visit pctcelltherapy.com/company/history/

NeoStem - Cell Therapy Development - Investors